Display options
Share it on

Drug Discov Today Dis Models. 2011;8(4):155-160. doi: 10.1016/j.ddmod.2011.03.003.

Cardiovascular Regulation in Obstructive Sleep Apnea.

Drug discovery today. Disease models

Michael G Ziegler, Milos Milic, Hamzeh Elayan

Affiliations

  1. University of California, San Diego, Medical Center, Department of Medicine, 200 West Arbor Drive, San Diego, CA 92103-8341, USA.

PMID: 22125570 PMCID: PMC3223912 DOI: 10.1016/j.ddmod.2011.03.003

Abstract

The majority of patients with obstructive sleep apnea (OSA) suffer from hypertension as a complication of both the metabolic syndrome and OSA. In animal studies, intermittent hypoxia that simulates changes seen in OSA leads to chemoreceptor and chromaffin cell stimulation of sympathetic nerve activity, endothelial damage and impaired blood pressure modulation. Human studies reveal activation of sympathetic nerves, endothelial damage and exaggerated pressor responses to sympathetic neurotransmitters and endothelin. Although treatment of the OSA normalizes sympathetic nerve responses, it only lowers blood pressure modestly. Agents that block the consequences of sympathetic over activity, such as β1 blockers and angiotensin antagonists have effectively lowered blood pressure. Diuretics have been less successful. Treatment of hypertensive patients with OSA usually requires consideration of both increased sympathetic nerve activity and the metabolic syndrome.

References

  1. J Hypertens. 2009 Jun;27(6):1243-51 - PubMed
  2. J Appl Physiol (1985). 2006 Jun;100(6):1974-82 - PubMed
  3. J Am Coll Cardiol. 2008 Aug 19;52(8):686-717 - PubMed
  4. Exp Physiol. 2007 Mar;92(2):391-8 - PubMed
  5. PLoS Med. 2009 Aug;6(8):e1000132 - PubMed
  6. J Hum Hypertens. 2009 Jul;23(7):431-43 - PubMed
  7. Chest. 2007 Aug;132(2):440-6 - PubMed
  8. J Cardiovasc Pharmacol. 1990 Dec;16(6):952-61 - PubMed
  9. Hypertension. 2010 Dec;56(6):1077-82 - PubMed
  10. Curr Med Res Opin. 2010 Aug;26(8):1925-32 - PubMed
  11. J Sleep Res. 1998 Sep;7(3):199-207 - PubMed
  12. Respir Physiol Neurobiol. 2007 Jul 1;157(1):148-53 - PubMed
  13. J Pharmacol Exp Ther. 1995 Sep;274(3):1067-71 - PubMed
  14. J Hypertens. 1997 Dec;15(12 Pt 2):1621-6 - PubMed
  15. Indian J Med Res. 2010 Feb;131:206-16 - PubMed
  16. Clin Res Cardiol. 2010 Aug;99(8):499-506 - PubMed
  17. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10073-8 - PubMed
  18. Ann N Y Acad Sci. 2009 Oct;1177:162-8 - PubMed
  19. J Hum Hypertens. 2010 Aug;24(8):532-7 - PubMed
  20. J Clin Hypertens (Greenwich). 2008 Mar;10(3):239-44 - PubMed
  21. Am J Hypertens. 2007 Jan;20(1):44-52 - PubMed
  22. Chest. 2010 Sep;138(3):528-35 - PubMed
  23. J Clin Invest. 1991 Jun;87(6):1953-7 - PubMed
  24. J Neurosci. 2010 Aug 11;30(32):10763-72 - PubMed
  25. Clin Sci (Lond). 2007 Sep;113(6):267-78 - PubMed
  26. Prog Cardiovasc Dis. 2009 Mar-Apr;51(5):371-80 - PubMed
  27. Hypertension. 2005 Apr;45(4):705-9 - PubMed
  28. Respir Physiol Neurobiol. 2010 Nov 30;174(1-2):156-61 - PubMed
  29. Pharmacol Ther. 2010 May;126(2):159-72 - PubMed
  30. Am J Cardiol. 2010 Apr 15;105(8):1135-9 - PubMed
  31. J Renin Angiotensin Aldosterone Syst. 2010 Sep;11(3):165-72 - PubMed
  32. Chest. 2001 Sep;120(3):887-93 - PubMed
  33. Am J Respir Crit Care Med. 2009 Jun 15;179(12):1159-64 - PubMed
  34. Hypertension. 1998 Dec;32(6):1039-43 - PubMed
  35. Curr Opin Pulm Med. 2008 Nov;14(6):530-6 - PubMed
  36. J Physiol. 2006 Dec 1;577(Pt 2):705-16 - PubMed
  37. Sleep Med. 2010 Mar;11(3):325-8 - PubMed
  38. J Appl Physiol (1985). 2004 Mar;96(3):1236-42; discussion 1196 - PubMed
  39. Cleve Clin J Med. 2007 Feb;74 Suppl 1:S34-6 - PubMed
  40. J Physiol. 2005 Oct 15;568(Pt 2):677-87 - PubMed
  41. Am J Hypertens. 1998 Mar;11(3 Pt 1):272-9 - PubMed
  42. J Auton Nerv Syst. 1996 Jan 5;56(3):184-90 - PubMed

Publication Types

Grant support